Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants

Trial Profile

Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs BCG vaccine (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Sponsors Serum Institute of India
  • Most Recent Events

    • 22 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 18 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 20 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top